April 2026 • PharmaTimes Magazine • 22-23
// PHARMA //
Fast and the curious
The 15 most kick-ass pharma products of the past 15 years
Over the past decade and a half, the pharmaceutical industry has delivered some of the most astonishing breakthroughs in modern medicine. And it’s just as well, without them this article would be written from a destroyed apartment block in the middle of a dystopian nightmare.
Indeed, from treatments that were once the stuff of science fiction to everyday products that have quietly transformed public health, the sector has reshaped what is possible for patients, clinicians and health systems.
It has also changed expectations. Folk now assume that innovation will be faster, smarter and more personalised than ever before.
Choosing the 15 greatest products of the past 15 years is no easy task. But some medicines stand out not only for their clinical impact, but for the way they have shifted entire therapeutic landscapes, opened new scientific frontiers or changed how society thinks about disease. Here are the products that have defined an era.
1. mRNA COVID-19 vaccines
It is impossible to overstate the significance of the first authorised mRNA vaccines. Pfizer‑BioNTech’s and Moderna’s COVID‑19 vaccines did more than help pull the world out of a global crisis. They validated a platform that had been in development for decades and proved that vaccines could be designed, manufactured and deployed at unprecedented speed. The ripple effects are still being felt, with mRNA now being explored for flu, RSV, HIV and even cancer.
2. GLP‑1 weight‑loss medications
Semaglutide and tirzepatide have become household names, and for good reason. Originally developed for diabetes, GLP‑1 drugs have transformed the treatment of obesity, a condition long underserved by effective therapies. Their impact goes far beyond weight loss. They are reshaping cardiovascular risk management, influencing consumer behaviour and forcing supply chains to evolve at pace. Few products have ever created such a cultural and clinical moment.
3. CAR‑T cell therapies
Fifteen years ago, the idea of reprogramming a patient’s own immune cells to hunt down cancer sounded like science fiction. Today, CAR‑T therapies such as Kymriah and Yescarta are saving the lives of people with otherwise untreatable blood cancers. They have also paved the way for a new generation of personalised cell and gene therapies that could redefine oncology for decades to come.
4. PCSK9 inhibitors
For millions of people with high cholesterol who cannot tolerate statins or need additional support, PCSK9 inhibitors like Repatha and Praluent have been game changers. They dramatically reduce LDL cholesterol and have helped shift the focus from managing cardiovascular disease to preventing it more aggressively.
5. Hepatitis C cures
The arrival of direct‑acting antivirals such as Sovaldi and Harvoni marked one of the most remarkable therapeutic revolutions of the century. Hepatitis C went from a chronic, life‑threatening condition to a curable disease with short treatment courses and minimal side effects. Few medicines have delivered such a clean, decisive victory.
6. Immunotherapy checkpoint inhibitors
Drugs like Keytruda and Opdivo have rewritten the rules of cancer treatment. By releasing the brakes on the immune system, they have delivered durable responses in cancers once considered untreatable. They have also become foundational therapies across multiple tumour types, inspiring a wave of combination approaches and next‑generation immunotherapies.
7. RSV vaccines for older adults
After decades of failed attempts, the approval of RSV vaccines for older adults and high‑risk groups represented a major public health milestone. These vaccines are already reducing hospitalisations and easing winter pressures on health systems, proving that innovation in infectious disease is far from over.
8. Gene therapies for rare diseases
Luxturna, Zolgensma and other pioneering gene therapies have shown what is possible when science targets the root cause of disease. Restoring vision, replacing faulty genes and offering one‑time treatments for conditions that were once fatal, these products have redefined hope for families affected by rare disorders.
9. Oral antivirals for COVID‑19
Medicines such as Paxlovid brought the fight against COVID‑19 out of hospitals and into homes. By reducing the risk of severe disease, they helped protect vulnerable populations and provided a crucial second line of defence alongside vaccines.
10. Biosimilars that expanded access
While not a single product, the rise of biosimilars deserves a place on this list. Over the past 15 years, biosimilars for insulin, monoclonal antibodies and oncology drugs have expanded access, reduced costs and increased competition. They have also forced the industry to rethink pricing and value in biologics.
10. Biosimilars that expanded access
While not a single product, the rise of biosimilars deserves a place on this list. Over the past 15 years, biosimilars for insulin, monoclonal antibodies and oncology drugs have expanded access, reduced costs and increased competition. They have also forced the industry to rethink pricing and value in biologics.
11. Long‑acting HIV prevention and treatment
Cabotegravir and other long‑acting injectables have transformed HIV care. For many people, the shift from daily pills to infrequent injections has improved adherence, reduced stigma and offered a new level of freedom. It is a powerful example of how innovation is not only about efficacy, but about fitting treatment into real lives.
12. Migraine CGRP inhibitors
For decades, migraine sufferers had limited options. The arrival of CGRP inhibitors such as Aimovig and Ajovy has provided targeted, effective prevention with fewer side effects. These medicines have helped millions regain control over a condition that can be profoundly disabling.
13. At‑home diagnostic technologies
From rapid COVID tests to advanced home blood‑testing kits, diagnostics have undergone a quiet revolution. Products that once required a clinic visit are now available on kitchen tables, empowering people to monitor their health and accelerating the shift towards decentralised care.
14. Novel antifungals
Fungal infections have long been an overlooked threat, particularly for immunocompromised patients. New antifungals such as ibrexafungerp have expanded the toolkit for clinicians and addressed growing concerns about resistance. It is a reminder that innovation matters across every corner of medicine, not just the headline‑grabbing areas.
15. Personalised cancer vaccines
Although still early, personalised cancer vaccines based on tumour‑specific mutations are one of the most exciting developments of the past 15 years. The first clinical successes suggest a future in which cancer treatment is tailored with extraordinary precision. They earn a place on this list not only for what they have achieved, but for what they promise.
Extraordinary progress
Taken together, these 15 products tell a story of rapid, mind-boggling scientific acceleration. They show how the industry has moved from broad‑spectrum treatments to precision medicine, from chronic management to cures, and from reactive care to prevention. They also highlight the growing importance of platforms such as mRNA, cell therapy and gene editing, which will shape the next wave of breakthroughs.
Most importantly, they demonstrate the power of sustained investment, global collaboration and scientific ambition. The past 15 years have been remarkable. The next 15 will venture beyond what we ever thought possible.
John Pinching is Editor, PharmaTimes